Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Completed · Phase 3 · Has a placebo group

Conditions studied: Obstructive Hypertrophic Cardiomyopathy

In brief

This is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM). Approximately 220 participants will be randomized to receive placebo or mavacamten.

Key facts

Study ID
NCT03470545
Run by
MyoKardia, Inc.
People needed
251
Starts
2018-05-29
Expected to finish
2020-05-06
Last updated by the study team
2021-10-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.